Natural disease history and characterisation of  molecular defects in ten unrelated patients with multiple sulfatase deficiency by unknown
Sabourdy et al. Orphanet Journal of Rare Diseases  (2015) 10:31 
DOI 10.1186/s13023-015-0244-7RESEARCH Open AccessNatural disease history and characterisation of
SUMF1 molecular defects in ten unrelated patients
with multiple sulfatase deficiency
Frédérique Sabourdy1,2*, Lionel Mourey3,4, Emmanuelle Le Trionnaire1, Nathalie Bednarek5, Catherine Caillaud6,
Yves Chaix7, Marie-Ange Delrue8, Anne Dusser9, Roseline Froissart10, Roselyne Garnotel11, Nathalie Guffon12,
André Megarbane13,14, Hélène Ogier de Baulny15, Jean-Michel Pédespan16, Samia Pichard15,
Vassili Valayannopoulos17, Alain Verloes18 and Thierry Levade1,2*Abstract
Background: Multiple sulfatase deficiency is a rare inherited metabolic disorder caused by mutations in the SUMF1
gene. The disease remains poorly known, often leading to a late diagnosis. This study aimed to provide improved
knowledge of the disease, through complete clinical, biochemical, and molecular descriptions of a cohort of
unrelated patients. The main objective was to identify prognostic markers, both phenotypic and genotypic, to
accelerate the diagnosis and improve patient care.
Methods: The phenotypes of ten unrelated patients were fully documented at the clinical and biochemical levels.
The long-term follow-up of each patient allowed correlations of the phenotypes to the disease outcomes. Each
patient’s molecular defects were also identified. Site-directed mutagenesis was used to individually express the
mutants and assess their stability. Characterisation of the protein mutants was completed by in silico analyses based
on sequence comparisons and structural models.
Results: The most severe cases were characterised by the presence of non-neurological symptoms as well as the
occurrence of psychomotor regression before 2 years of age. Nine novel SUMF1 mutations were identified. Clinically
severe forms were often associated with SUMF1 mutations that strongly affected the protein stability and/or catalytic
function as predicted from in silico and western blot analyses.
Conclusions: This detailed clinical description and follow-up of a cohort of patients, together with the molecular
characterisation of their underlying defects, contribute to improved knowledge of multiple sulfatase deficiency.
Predictors of a bad prognosis were the presence of several non-neurological symptoms and the onset of
psychomotor regression before 2 years of age. No strict correlation existed between in vitro residual sulfatase activity
and disease severity. Genotype–phenotype correlations related to previously reported mutants were strengthened.
These and previous observations allow not only improved prediction of the disease outcome but also provision of
appropriate care for patients, in the expectation of specific treatment development.
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Multiple sulfatase deficiency (MSD; MIM #272200), also
known as Austin disease or mucosulfatidosis, is a very
rare autosomal recessive disorder. It was first described
in 1964 by Austin as an atypical form of metachromatic
leukodystrophy (MLD), a disease caused by deficient
arylsulfatase A activity [1,2]. In addition to the neurode-
generative syndrome typically observed in MLD, the pa-
tients described by Austin presented with symptoms
reminiscent of other sulfatase deficiencies, such as
mucopolysaccharidoses (MPS) and X-linked ichthyosis.
Biochemical analyses revealed that the activities of sev-
eral sulfatases were indeed simultaneously decreased in
the cells of these patients. MSD is now clearly defined as
a single genetic entity characterised by the deficient ac-
tivity of all cellular sulfatases, regardless of their subcel-
lular localisation [3,4]. In fact, all 17 currently known
sulfatases, including lysosomal, microsomal, Golgi, and
cell surface sulfatases, are concomitantly affected. Pa-
tients with MSD exhibit combined symptoms from sev-
eral individual sulfatase deficiency disorders, leading to
heterogeneous clinical presentations. Based on the main
symptoms and ages of their onset, four clinical subtypes
of MSD with varying severity have been distinguished
[5]. The neonatal subtype is characterised by MPS-like
symptoms occurring in the first months of life, and usu-
ally leads to early death before 1 year of age. The late
infantile forms are rather dominated by progressive neu-
rodegeneration, such as that observed in MLD. The dis-
tinction between the severe and mild late infantile
subtypes is based on the age of onset of symptoms (i.e.,
before or after 2 years of age), as well as the number of
typical signs of individual sulfatase deficiencies. The ju-
venile subtype is characterised by a late onset and atten-
uated symptoms.
The issue of how a single gene defect can affect a
whole enzyme family remained unsolved for four
decades, until the molecular basis of MSD was simultan-
eously discovered by two groups [6,7]. Mutations in the
Sulfatase Modifying Factor 1 (SUMF1) gene (chromosome
3p26.1) were found to lead to a functional defect in
formylglycine-generating enzyme (FGE), a critical protein
involved in the post-translational activation of all sulfatases
in the endoplasmic reticulum. FGE oxidises a cysteine resi-
due located within a consensus CxPxR sequence shared by
all sulfatases to generate a formylglycine. This cysteine
oxidation is absolutely required by sulfatases to exert their
enzymatic activity.
Despite the recent identification of the molecular
bases underlying MSD, the disease is still under-
diagnosed and poorly known. Less than 50 patients suf-
fering from this rare disease have been reported to date
[8]. Although an animal model of the disease has been
generated [9], its pathophysiology remains unclear.Disturbed autophagy has been described [10]. Fur-
thermore, although gene therapy trials have recently
been performed on animal models [11], no specific
therapy is yet available for this very severe disorder.
Improved knowledge regarding the molecular bases
of MSD is thus needed.
Since the discovery of FGE, significant advances have
been made toward the clarification of its molecular and
biochemical properties. Determination of the three-
dimensional structure of the protein has contributed to
the identification of several critical residues involved in
FGE stability and catalytic activity [12-14]. In addition,
analyses of the SUMF1 mutations found in MSD pa-
tients have proven to be very informative. Specifically,
about 30 different mutations have been reported to date.
Some of these mutant genes were individually expressed
to assess their impact on FGE expression and catalytic
activity [6,7,12,15-17]. Taken together, the resulting data
suggested an original enzymatic mechanism for the sul-
fatase cysteine oxidation to formylglycine. Previous stud-
ies have also allowed some conclusions to be drawn
regarding genotype–phenotype correlations. For ex-
ample, mutations affecting both the stability and cata-
lytic activity of FGE seem to be responsible for the most
severe phenotypes, whereas mutations that exclusively
impair one of these properties tend to be associated with
milder forms of the disease [18].
To further improve our understanding of MSD, we re-
port here 10 novel unrelated patients whose phenotypes
and genotypes were characterised. Based on complete
descriptions of the clinical presentation and disease out-
come of each patient, as well as the associated biochem-
ical and molecular defects, features that can influence
the prognosis of MSD are presented.
Methods
Patients
Ten patients from unrelated families in which clinical
examination and lysosomal enzyme analyses led to MSD
diagnosis were investigated for SUMF1 mutations. De-
tailed clinical features and biochemical data are pre-
sented in the results section. Signed, informed consent
was obtained from each patient and their parents.
Genetic analyses
Genomic DNA was isolated from peripheral blood
leukocytes (Nucleospin II, Macherey-Nagel, Germany).
Exons 1 through 9 of the SUMF1 gene including intron-
exon junctions were individually amplified [19] and
sequenced in both directions. For cDNA analysis,
RNA was isolated from Epstein-Barr virus-transformed
lymphoid cells (SV Total RNA extraction kit, Promega),
reverse-transcribed and amplified (primer sequences
are available upon request). DNA sequencing was
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matic sequencer.
Expression of wild-type and mutant FGE proteins
Site-directed mutagenesis of the SUMF1 cDNA
The pSUMF1-3xFlag plasmid was kindly provided by
Dr. A. Fraldi (Naples, Italy) [20]. This construct was
used as a template for site-directed mutagenesis using
the QuickChange Site-Directed Mutagenesis Kit (Strata-
gene) and primer pairs are listed (Additional file 1). The
SUMF1 cDNA of patient 7 carrying the V174-P318dup
duplication was amplified and inserted into p3XFlag-
CMV, in frame with the Flag tag. All recombinant
vectors were purified (Qiagen Plamid Maxi kit) and the
inserts sequenced.
Cell transfection
HEK293Tcells were grown in a humidified 5% CO2 atmos-
phere at 37°C in DMEM containing Glutamax (2 mM) and
10% heat-inactivated fetal calf serum (FCS). Cells were
transfected with 5 μg of either pSUMF1-3xFlag, pR236X-
Flag, pN259S-Flag, pG263V-Flag, pA298E-Flag, pY340H-
Flag, pR343S-Flag, or pV174-P318dup-Flag plasmids, using
Superfect (Qiagen). After 48 h incubation, HEK293T cells
were washed with PBS and harvested. Cell pellets were fro-
zen at −80°C until use.
Western blot analysis
Cell pellets were resuspended in lysis buffer (Cell Signaling)
containing 1 mM PMSF and a protease inhibitor cocktail
(Complete, Roche). Protein extracts (25 μg) were loaded
and separated in a 10% SDS-polyacrylamide gel and trans-
ferred to a nitrocellulose membrane (Bio-Rad). FGE was
detected by using an anti-Flag mouse monoclonal antibody
(1:1000, Sigma). Anti-β-actin and goat anti-mouse second-
ary antibodies were from Cell Signaling.
In silico analysis of FGE mutants
The Polyphen software was used to predict the possible
impact of amino acid substitutions on the structure and
function of the FGE protein [21]. The Human Splicing
Finder software [22] allowed to predict potential tran-
scripts induced by mutations occurring at splicing sites.
The Swiss-model program [23-25] was used to deduce
hypothetical structures from the sequences of FGE mu-
tants. The 1Y1E.pdb and 1Z70.pdb structures were used
as templates, and homology models were produced using
the Automated mode. Structure visualization and analyses
were carried out using the PyMOL program [26].
Results
Clinical data
Patient 1 was born to non-consanguineous parents after
an uneventful pregnancy. The birth parameters were inthe normal range (BW, 3.150 kg; BL, 50.5 cm; HC,
34 cm). The disease was revealed by mild motor delay
with hypotonia contrasting with good verbal abilities
during the first 3 years of life. Although there was no
motor regression, cerebellar ataxia with generalised
tremor appeared between 4 and 7 years, followed by nys-
tagmiform movements revealing retinitis pigmentosa.
MRI showed a thin corpus callosum and cerebellar atro-
phy. In the following years, the patient improved his
motor abilities and language. No further neurological de-
terioration, swallowing difficulties, or spasticity were
noted. He developed mild ichthyosis that became prom-
inent during the summer period. At the last clinical
evaluation, he was 12 years old. He measured 143 cm,
and weighed 32.9 kg (normal range). His skin appeared
normal. He had no walking difficulties, but experienced
tremor of the upper limbs. His major impairment was
visual loss.
Patient 2 was born to non-consanguineous parents. He
presented with an inguinal hernia at birth (repaired sur-
gically at 16 months) and experienced repeated otitis
media in the first year of life. He required tympanostomy
and tonsillectomy. Speech and psychomotor delays were
noticed around 2 years of age, with delay in toilet train-
ing and socialisation difficulties suggesting atypical aut-
ism. The disease progressed slowly with minor physical
changes: he displayed claw fingers, abnormal ear helix,
and microretrognathia. MRI showed demyelination,
ventricular enlargement, and cerebral atrophy. In the fol-
lowing years, the patient developed ichthyosis, psycho-
motor regression, and growth retardation. He was able
to communicate using a few words until 7 years of age,
but then progressively lost speech. Sleep disturbance
was noticed from the age of 8 years, along with signs of
retinitis pigmentosa. At his last follow-up at 11 years of
age, he presented with MPS-like dysmorphism associated
with severe spasticity. His weight was 21.5 kg (< −3 SD) for
a height of 117 cm (< −3 SD).
Patient 3 was born to non-consanguineous parents
after a pregnancy marked by third trimester foetal dis-
tress. She had low birth weight and height (BW,
2.670 kg (−1.5 SD); BL, 46 cm (−2 SD); HC, 34.5 cm).
The disease was revealed by markedly delayed motor
skills at 12 months and hypotonia at 18 months, along
with delayed verbal abilities. She crawled at 18 months
and walked unsupported at 2.5 years. Speech regression
and loss of communication occurred around 2.5 years of
age. She could pronounce a few words at 5 years. Brisk
tendon reflexes at the lower limbs and truncular ataxia
were noticed at 6 years. Brain MRI showed mild cortical
atrophy, and cerebellar atrophy with vermian hypoplasia.
She also presented with severe limb vasomotor impair-
ment, mimicking Raynaud’s syndrome. At 7 years of age,
the patient was still able to walk without assistance. She
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disyllabic words. Although autism spectrum disorder
was not formally assessed, her behaviour showed many
autistic features, such as poor visual contact and hand
stereotypies, for which applied behaviour analysis ther-
apy was set up. Ophthalmological evaluation revealed
oculomotor apraxia and severe myopia. The parents
noted progress in manual skills, walking, social interac-
tions, and comprehension. At 9 years of age, clinical
examination revealed hepatomegaly, hip laxity, and en-
hanced ataxia. She lost autonomous walking ability and
needed support to climb stairs. At the age of 10 years
and 6 months, she measured 124.5 cm (−2.5 SD),
weighed 26 kg (−2 SD), and had a HC of 51 cm (−1.5 SD).
She had no facial dysmorphism.
Patient 4 was born to non-consanguineous parents
after an uneventful pregnancy (BW, 2.740 kg (−1.5 SD);
BL, 46 cm (−2 SD)). Her neurological development was
mildly delayed: she was able to walk at 18 months, and
pronounced her first words between 18 and 24 months
of age. From 24 to 36 months of age, her mother
reported a slowdown in language acquisition, with fluc-
tuation in speech production. The patient suffered from
recurrent serous otitis and infections of the upper re-
spiratory tract that required adenotonsillectomy. She
attended school, and started speech therapy and psycho-
motor rehabilitation. She was hospitalised at the age of
3 years and 5 months because of psychomotor delay and
major feeding difficulties. Unsupported walking was pos-
sible, but complicated by frequent falls. She was able to
climb stairs with assistance. Speech was delayed and she
could only pronounce 10 isolated words. Neurological
examination revealed ataxia, brisk tendon reflexes, and
hypotonia of the upper and lower limbs. Microcephaly
was noted (HC: 47 cm (−2 SD)). Audition was assessed
by auditory-evoked responses, revealing mixed hearing
loss. Brain MRI performed at 4 years and 8 months
showed cerebellar hypoplasia. Taken together, all of
these findings pointed to a progressive neurological dis-
ease, which was finally diagnosed as MSD. At the last
evaluation, she was 6 years and 2 months old, still able
to walk 50 meters alone but with difficulties due to a
marked ataxia. She could pronounce only a few disyllabic
words but interacted well with her environment. She was
agitated and suffered from sleep disturbances.
Patient 5 was born to non-consanguineous parents
after a normal pregnancy (BW, 3.990 kg; BL, 51 cm; HC,
34 cm (−1 SD)). He was hospitalised during the first year
of life for feeding difficulties. Ichthyosis was noticed. He
was able to sit at 10 months of age, and walked unsup-
ported at 19 months, but with frequent falls. His first
words appeared around 20 months of age. However, the
patient presented behavioural disturbance, walking diffi-
culties, and loss-of-consciousness spells. At 3 years ofage, clinical examination revealed mild facial dysmorph-
ism (arched eyebrows, high arched palate) and mild
ataxia associated with swallowing difficulties. MRI
showed hyperintense signals in the periventricular white
matter compatible with delayed myelination, and an
abnormal corpus callosum. After the age of 4 years, his
walking ability deteriorated, leading to frequent falls with
worsening of the ataxia, and subsequent loss of walking
at 7 years. Sphincter control was lost at 4.5 years. Other
symptoms included hepatomegaly, hypersialorrhoea,
absence seizures, and very agitated behaviour. Speech
remained extremely delayed.
Patient 6 was born to first-cousin parents. He was
2 years old when psychomotor delay, generalised tremor,
and ataxia were noticed. He could walk a few steps with
assistance and displayed irritable behaviour. Shortly
afterward, he experienced severe and rapid regression
with global hypotonia and severe ataxia. Brain MRI re-
vealed progressive cortical and cerebellar atrophy. Social
contact was eventually lost (no speech and no visual
contact). Morphologically, he presented with hirsutism
and delayed growth with delayed bone age. At the last
follow-up at 8.5 years of age, the patient was unable to
sit and displayed spasticity leading to hip dislocation.
Patient 7 was the second child of first-cousin parents.
He presented with neonatal ichthyosis, repeated otitis,
and bronchitis since 3 months of age. He experienced
hypotonia from the first month of life, was able to sit at
1 year, and could stand up with assistance at 2 years.
MRI showed delayed myelination. He did not present
MPS features, but exhibited progressive microcephaly.
His condition rapidly deteriorated. He developed retinitis
pigmentosa at 3 years without corneal clouding, followed
by swallowing difficulties from 4 years of age. At 6 years
of age, he was bedridden and suffered from severe spas-
ticity. His weight was 16.5 kg (−3 SD) and his height was
98.5 cm (<3 SD).
Patient 8 was born at term to healthy non-consanguineous
parents after a pregnancy marked by reduced foetal
movements and oligoamnios. At birth, the only symp-
tom was the presence of dry skin. At 2 months of age,
he displayed signs of tracheomalacia and hepatosplenome-
galy, followed by corneal opacities at 9 months. Psycho-
motor delay and severe muscular hypotonia were noted
when he was 1 year old. He could walk with help and
could pronounce a few simple words at 2 years. By the age
of 5 years, he had lost social contact and become bedrid-
den. Serial MRI examinations revealed delayed myelin-
ation. The skin was ichthyotic, and skeletal deformities
(pectus carinatum and bowed legs) were noted. Hearing
loss was found at 6 years of age. He died a few months
later from respiratory complications.
Patient 9 was born at 35 weeks of gestation by cae-
sarean section following foetal cardiac arrhythmia.
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nios were noticed during pregnancy. At birth, the patient
suffered from severe respiratory distress caused by choanal
atresia. The first months of life were marked by severe
growth retardation and repeated upper airway infections.
Psychomotor delay was noted at the age of 4 months.
However, at 1 year of age, the patient was able to sit, stand,
and crawl. Ophthalmological examination revealed bilat-
eral cataracts and retinal atrophy. Skeletal X-rays revealed
vertebral anomalies. Ichthyosis and hepatosplenomegaly
were also noticed. The child retained good social contact
with her environment. MRI performed at 17 months
showed mild hyperintensities in the frontal lobe white
matter. Motor and mental regression occurred from the
age of 2 years. Swallowing difficulties led to malnutrition
and subsequent enteral feeding from the age of 2 years
and 9 months. Communicating hydrocephalus was diag-
nosed at 3 years and 3 months, and associated with vomit-
ing, drowsiness, and pyramidal signs. She died at the age
of 3 years and 9 months.
Patient 10 was the second child of non-consanguineous
parents. During the pregnancy, nuchal translucency was
noticed at 9 weeks, followed by intrauterine growth re-
tardation. At birth, she presented respiratory distress, axial
hypotonia associated with limb hypertonia, pectus excava-
tum, thoracolumbar kyphosis, and MPS-like dysmorphic
features. In the following months, she suffered from
recurrent otitis and bronchitis requiring surgical inter-
vention, severe deafness, and severe hydrocephaly requir-
ing ventriculo-peritoneal shunting at 26 months. Severe
sleep apnoea and bilateral inguinal hernia were also
present, and feeding difficulties required gastrostomy
tube feeding at 2.5 years of age. She presented severe dys-
ostosis that required bracing. She died at the age of
3 years and 4 months.
The main clinical features of the patients are sum-
marised in Table 1. Based on the classification previously
proposed by Eto and coworkers [5], which takes into
account the main symptoms and their ages of onset, spe-
cific clinical subtypes (i.e., juvenile, late infantile mild,
late infantile severe, neonatal severe) were attributed to
the patients. The phenotype of Patient 1 was of particu-
lar interest, because only rare cases of juvenile forms of
MSD have been published to date. The above classifica-
tion did not perfectly correlate with the disease courses
and severities, as some patients within the same group
displayed faster disease progression than other patients
(see Disease severity, Table 1).
Biochemical data
The residual sulfatase activities measured in the patients’
leukocytes are shown in Table 2. To allow comparisons
among data obtained from different laboratories, the sul-
fatase activities are presented as percentages of controlvalues. No clear correlations appeared between the re-
sidual enzyme activity of a given sulfatase and the dis-
ease severity. However, when patients were classified
according to the average residual activities of all tested
sulfatases, this parameter tended to be inversely corre-
lated with the disease severity. Only Patients 4 and 5
showed discordant residual sulfatase activities with re-
spect to their disease severity. Of note, similarly elevated
activities were observed for Patient 5 when controlled in
immortalised lymphoblasts, and the activities were even
higher in fibroblasts (data not shown).
Molecular analyses
Genomic DNA and/or cDNA sequencing revealed changes
in the SUMF1 sequence on both alleles of each patient.
We thus identified 13 different mutations, nine of
which have not previously been described (Table 3).
The mutations included nonsense, missense, and spli-
cing site mutations. It is noteworthy that a duplication
of four entire exons without inducing a frameshift was
identified in the cDNA of Patient 7. Sequencing of all
exons and intron–exon junctions in the genomic DNA
failed to reveal any anomaly. Similarly, the skipping of
exon 3 and exon 5 in the cDNA of Patient 5 and Patient
10, respectively, did not lead to a frameshift. However,
the use of specific primers revealed that the mutation
leading to exon 3 skipping in Patient 5 generated an-
other transcript retaining the first four nucleotides of
intron 3 and lacking the first seven nucleotides of exon
4. This splicing could be predicted by Human Splicing
Finder software [22]. Unexpectedly, this change in the
genomic sequence induced the deletion of only one ala-
nine residue at position 175.
To further characterise the impacts of the SUMF1
mutations on the expression of the protein, we indi-
vidually expressed some of the mutants identified.
Protein expression and stability were evaluated by
western blotting analysis after transient overexpres-
sion of the C-terminally Flagged mutants in HEK293T
cells (Figure 1). The anti-Flag antibody revealed three
bands, comprising an approximately 42-kDa band cor-
responding to full-length FGE and two bands corre-
sponding to N-terminally processed forms intended
for secretion, as previously reported [27]. While the
p.Y340H and p.R343S mutants were expressed at the
same level as the wild-type (wt) protein, the p.G263V
and p.N259S mutants showed reduced expression. The
p.A298E mutant was expressed at an intermediate level.
As expected, the mutant carrying the p.R236X non-
sense mutation could not be detected, because the
C-terminal Flag-tag was not translated in this con-
struct. The p.V174-P318dup mutant carrying the du-
plication of four exons was efficiently expressed and
appeared at around 65 kDa.
Table 1 Clinical presentation of MSD patients
Patients 1 2 3 4 5 6 7 8 9 10
Origin France France France France France Pakistan Turkey Lebanon France France
Consanguinity - - - - - + + - - -
Antenatal manifestations
(oligoamnios, IUGR)




























Psychomotor retardation ++ ++ +++ ++ +++ ++ +++ +++ +++ +++
Neurodegeneration
Neurological symptoms
+ ++ ++ ++ ++ ++ ++ +++ +++ +++
Ichthyosis + + + - +++ - +++ +++ +++ ++
Dysmorphism - + - - ++ - - - - +++
Organomegaly - - - - + ND - +++ +++ ++
Skeletal changes - - - + - + - +++ +++ +++
Heart disease - - - - - - - - - ++
Corneal clouding - - - - - - - +++ - -
Retinitis pigmentosa + + - - - - + - - +++
Hydrocephalus - - - - - - - - - +++





























No From 6 years From 2.5 years No From 3.5 years From 2 years From 2 years From 2 years From 2 years ND











Dead at 6 years Dead at 3 years
and 9 months
Dead at 3 years
and 4 months
Clinical subtype [5] J LIM LIM LIM LIM LIM LIM LIS LIS NS
Disease course very slow slow slow slow slow fast fast fast very fast very fast
Disease severity was estimated as described [5]. Age at onset: +++, < 2 years; ++, 2–4 years; +, > 4 years. Disease course was appreciated as follows: very slow: only mild neurological and motor involvement at 12 years
old; slow: able to walk at least up to 6 years old; fast: loss of contact and/or bedridden state occurring before 7 years old; very fast: death occurring before 4 years old. Abbreviations: IUGR Intrauterine growth retardation,














Table 2 Biochemical findings in MSD patients
Patients 1 2 3 4 5 6 7 8 9 10
Sulfatases (% of control)
ArsA 4 14 10 5 3 3 5 2 8 7
ArsB 16 13 6 5 ND 7 ND 9 4 ND
ArsC 15 6 ND 4 ND 2 ND ND 7 ND
IDS 7 3 4 2 20 ND 3 1 ND 0
SGSH ND 19 ND ND ND ND ND 0.5 ND 0
G6S ND 0 ND ND ND ND ND ND ND 2
GalNS ND 5 ND ND 28 2 ND ND ND ND
Mean 11 9 7 4 17 4 4 3 6 2
Urinary GAG (mg/mmol creatinine) 0.1; 0.2 GAG: 18.8; 14.4 GAG: 0.3 GAG: 18.1; 11 ND GAG: 12.5 ND GAG: 22 GAG: 33
(control: <1.8) (control: <13) (control: <2.6) (control: <13) (control: <3.3) (control: <8) (control: <6.3)
HS: 20%; HS:+++ HS: traces HS++++; CS+++ HS: 88.5%; HS+++; CS+++
CS: 80%; DS: +++ DS+; KS: traces CS: 11.5%; no DS++; no KS
no DS DS; no KS
Urinary sulfatides (nmol/mmol creatinine) 88 (control: < 40) positive ND positive 263 (control: < 40) ND ND ND ND ND
Sulfatase activities were determined on lysates of peripheral blood leukocytes, and are expressed as percentage of the values measured in control samples. Abnormal urinary excretion of glycosaminoglycans and sulfatides is
indicated (note that distinct methods were employed by different laboratories). Abbreviations: ArsA arylsulfatase A, ArsB arylsulfatase B, ArsC arylsulfatase C, IDS iduronate 2-sulfatase, SGSH N-sulfoglucosamine sulfohydrolase,














Table 3 SUMF1 mutations identified in MSD patients
Patient Mutation Affected Exon Mutant protein Predicted effect of missense mutations
on the FGE structure
1 c.[463 T > C] + [1029G > T] 3 and 9 p.[S155P] + [R343S] p.S155P: loss of three hydrogen bonds
and steric clash with Ala186 [12].
p.R343S: direct interaction with both
sulfhydryl groups of the catalytic
Cys336/Cys341 pair. Might affect
substrate binding and reactivity.
2 c.[836C > T] + [836C > T] 6 p.[A279V] + [A279V] Steric clash with Phe275 and Ala283 [12].
3 c.[836C > T] + [836C > T] 6 p.[A279V] + [A279V] Idem
4 c.[836C > T] + [836C > T] 6 p.[A279V] + [A279V] Idem
5 c.[893C > A] + [519 + 4A > G] 7 and 3 p.[A298E]+ [A149_A173del, A175del] p.A298E: neither affects FGE fold nor
binding to the Ca2+ ion at site 2.
6 c.[788G > T] + [788G > T] 6 p.[G263V] + [G263V] Steric clash with Thr263 and Thr270 [12].
7 c.[520_954dup (+)
520_954dup]
4 to 7 p.[V174_P318dup] + [V174_P318dup]
8 c.[706C > T] + [1045C > T] 5 and 9 p.[R236X] + [R349W] p.R349W: loss of five interactions [12].
Should affect protein fold in the
vicinity of the active site.
9 c.[132_133insG] + [1045C > T] 1 and 9 p.[V45fsX75] + [R349W] idem
10 c.[776A > G;1018 T > C] +
[725 + 1G > C]
6, 9 and 5 p.[N259S; Y340H]+ [P202_R242del] p.N259S precludes binding to Ca2+ ion
at site 1. p.Y340H should not induce
major structural changes.
Novel mutations are indicated in bold characters. Patients are listed as in Table 1, where they are ranked on an ascending scale of disease severity.
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ability of each mutant to restore sulfatase activities in a
defective MSD fibroblast cell line. For this purpose, the
mutants were stably overexpressed in MSD fibroblasts,
and the arylsulfatase A, B, and C activities were mea-
sured. Unfortunately, the expression levels of FGE in the
stable transfectants were not sufficiently high to allow
accurate assessment of the protein functionality. Of
note, however, and despite several attempts, no stable
cell transfectants could be obtained for the p.V174-
P318dup mutant, suggesting that it may exert some
cytotoxicity.Figure 1 Western blot analysis of overexpressed wild-type and mutan
encoding C-terminally flagged wt or mutant FGE (25 μg protein) were asse
panel: loading control. NT, not transfected; DUP, p.V174-P318dup.Structural analyses were performed to complete the
characterisation of the missense SUMF1 mutations,
based on the known 3D structures of FGE [12,13]
(Figures 2 and 3).
The structural consequences of the p.S155P, p.G263V,
p.A279V, and p.R349W mutations have already been re-
ported [12], and will not be discussed here. Besides the
previously described p.S155P mutation, Patient 1 also
carried the novel p.R343S substitution. Arg343 is strictly
conserved within all species, and the p.R343S mutation
is “probably damaging” (with the highest score) accord-
ing to the Polyphen prediction software. Interestingly,t FGE. Lysates of HEK293T cells transiently transfected with a vector
ssed for FGE expression by Western-blot. Upper panel: FGE. Lower
Figure 2 Representation of FGE and the main mutated residues identified in this and previous studies. Cartoon representation of the FGE
structure (PDB code 1Y1E) with helices in blue, beta-strands in violet, and loops in yellow. Represented in ball-and-stick and labelled are (i) essential
or important residues for substrate binding and catalytic activity (orange carbon atoms), (ii) residues whose mutations have been previously
described (magenta carbon atoms) [6,16,17,27], and (iii) newly identified mutations (cyan carbon atoms). N, O, and S atoms are in blue, red,
and green, respectively. The two structural calcium ions are also represented (green spheres).
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formations in the wt enzyme structure, points toward
and establishes a long-range interaction with the sulfhy-
dryl group of Cys341 when the catalytic Cys336/Cys341
pair is reduced (Figure 3A, left). The substitution of
Arg343 to a serine, wherein the molecular modelling re-
vealed that the hydroxyl group may directly interact with
the sulfhydryl groups of both Cys341 and the more
reactive Cys336 (dS343OG-C341SG = 3.6 Å; dS343OG-
C336SG = 2.9 Å) (Figure 3A, right) [14], might have im-
portant consequences in terms of substrate binding and
reactivity. Among the other newly identified mutations,
Patient 5 carried a p.A298E substitution. Ala298 is well-
conserved among animal species, but sometimes re-
placed by a valine. The Polyphen software predicted that
this mutation is “possibly damaging” with a score of
0.893. In the structure of wt FGE, the carbonyl group of
A298 is involved in the perfect octahedral coordination
of the Ca2+ ion at site 2 (Figure 3B, left). Molecular
modelling of p.A298E indicates that a glutamate side-
chain could easily be accommodated by the FGE fold
and that the main-chain carbonyl group would point inthe same direction as in the wt protein, and probably
not affect the Ca2+ ion coordination sphere (Figure 3B,
right). Finally, with respect to Patient 10, Asn259 was
previously proposed to be a critical residue for the FGE
protein (see Discussion). In the p.N259S mutant iden-
tified in Patient 10, the overly-long distance between
the oxygen atom of the serine hydroxyl group and the
calcium ion (3.5 Å) would preclude the establishment
of a coordinate bond (Figure 3C, right). The Tyr340
residue, which is also mutated to histidine in Patient
10, is very close to the catalytic site of FGE. Neverthe-
less, the substitution of the tyrosine by a histidine
does not induce any steric hindrance, because the aro-
matic and imidazole groups are approximately the same
size.
Discussion
The clinical features and gene defects of 10 new patients
affected with the rare disorder MSD were analysed.
Through detailed clinical descriptions of each patient,
together with biochemical and molecular characterisa-
tions, we investigated the possible predictive values of
Figure 3 Structural modifications of FGE due to mutations identified in MSD patients. Details of the conformation of wt (left panel) and
mutant (right panel) FGE are shown for three missense mutations: p.R343S (A); p.A298E (B) and p.N259S (C).
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and outcome.
Clinical heterogeneity, correlation between biochemical
and clinical phenotypes
In the search for prognostic factors, we first determined
the extent of disease severity for each patient. The dis-
ease course, assessed through the clinical history and
age of death (when available), appeared to be a relatively
good marker of disease severity (see Table 1). Mean-
while, the clinical subtypes (i.e., juvenile, late infantile
mild, late infantile severe, neonatal severe) were distin-
guished according to the classification proposed by Etoand coworkers [5], which takes into account the main
symptoms and their ages of onset. The subtypes ob-
tained with this historical classification were not per-
fectly correlated with the disease courses. Indeed,
some patients within the same clinical subtype dis-
played more rapid disease progression than other pa-
tients (see Table 1). We thus chose to define the
disease severity according to the disease course and
then aimed to determine the clinical features that could
influence the prognosis.
The age at onset of the first symptoms appeared to be
highly variable and did not correlate well with the dis-
ease course and severity (e.g., in Patient 2). Psychomotor
Sabourdy et al. Orphanet Journal of Rare Diseases  (2015) 10:31 Page 11 of 14retardation and hypotonia were common to all patients,
around the age of 2 years. While these symptoms
appeared at an earlier time in the most severe forms
(before 1 year of age for Patients 7, 8, 9, and 10), this
correlation did not hold true for all patients (e.g. Patient
3 with psychomotor delay noticed as early as 1 year of
age with slow disease evolution). The onset of psycho-
motor regression appeared to be a more accurate indica-
tor (see “ongoing psychomotor regression”, Table 1).
When observed at 2 years of age, it was associated with
rapid disease progression, whereas later onset was linked
to a slower disease course. Finally, the presence of sev-
eral non-neurological symptoms (e.g., dysmorphism,
skeletal abnormalities, organomegaly) before 2 years of
age predicted a more severe and rapid form of the dis-
ease (see Table 1, Patients 8, 9, and 10). Taken together,
these observations identify two major clinical features
that could be in favour of rapid progression of the dis-
ease, namely the presence of several non-neurological
symptoms and the onset of psychomotor regression be-
fore 2 years of age.
We also examined the possibility of stratifying patients
based on the mean residual sulfatase activities. Our ob-
servations indicated the presence of a trend for the re-
sidual sulfatase activities in leukocytes to be inversely
correlated with the disease severity. However, this con-
clusion, which corroborates a previous statement [5],
can only be drawn in a global context of comparison. It
would be illusive to give a prognosis based solely on the
measurement of sulfatase activities, because the results
are clearly dependent on the nature of the biological
samples examined [28], the enzyme assay protocol, and
the sulfatase under analysis [16]. In addition, our results
confirmed previous observations indicating that sulfa-
tases are heterogeneously affected by SUMF1 defects
[16]. Analyses of additional MSD cases are warranted to
investigate whether certain sulfatases are preferentially
affected by the identified SUMF1 mutations, or whether
the heterogeneous impacts arise through epigenetic or
environmental factors.
Molecular analysis and genotype-phenotype correlations
More than 30 SUMF1 mutations have been reported to
date. The impacts of many of these mutations on the
FGE structure, subcellular localisation, and activity have
been characterised (see Additional file 2). Hence, several
attempts to establish genotype–phenotype correlations
have been made, outlining some concepts. The neonatal
severe form of the disease may be caused by a combin-
ation of nonsense or missense mutations directly affect-
ing the FGE catalytic site [18]. Missense mutations with
severe impacts on either the protein stability or catalytic
activity would lead to severe phenotypes, whereas those
only partially affecting the protein stability would beassociated with milder phenotypes [27]. Finally, the hu-
man mutations may all be hypomorphic, although this
statement has been challenged by a severe neonatal case
associated with nonsense mutations in both alleles [27].
The analyses of the 10 MSD patients reported here
allowed further examination of genotype–phenotype
correlations. Among the 13 SUMF1 molecular defects
identified, nine were novel mutations, comprising four
missense mutations, two nonsense mutations, one dupli-
cation, and two splice site mutations. The most striking
observation related to Patient 1. This patient carried the
previously described p.S155P mutation. Ser155 lines the
substrate-binding groove. Four homoallelic p.S155P
cases have been reported to date [16,27], and all four pa-
tients had severe disease presentation. Although discord-
ant results were obtained in vitro, this mutation clearly
affected the FGE expression and activity (2% of wt) [27].
In Patient 1, the other allele carried the newly identified
p.R343S substitution. Our results suggested that this
substitution may impact the FGE catalytic activity. Thus,
there is a discrepancy between the clearly attenuated
phenotype observed in this patient and his genotype.
Once more, these observations underscore the real diffi-
culty in establishing rules about genotype–phenotype
correlations.
The p.A279V mutation has already been reported else-
where [17]. Together with Patients 2, 3, and 4, there are
now four reported French patients homozygous for this
mutation despite being born to non-consanguineous
parents. Therefore, the p.A279V mutation is likely to be
relatively common in the French population. Moreover,
all four patients presented a late infantile mild pheno-
type. In addition, our three patients exhibited similar,
relatively slow deterioration. These observations under-
line a genotype–phenotype correlation for this mutation.
Patient 5 carried the p.A298E substitution. In our
hands, this substitution by glutamic acid appeared to
have little impact on the protein expression and con-
formation (Figures 1 and 3B). On the other allele, the
patient carried a mutation in the donor site of intron 3,
leading to exon 3 skipping. Skipping of exon 3 has
already been reported along with nonsense mutations in
at least two patients, leading to neonatal severe pheno-
types [6,7,27]. It is thus consistent that, when this muta-
tion was associated with a missense mutation, such as in
Patient 5, it led to a milder phenotype. A third transcript
was identified in Patient 5, which induced deletion of
Ala175 at the protein level. Residue 175 is located in the
Ser163-Ala176 segment that is absent from the FGE pro-
tein structure as a result of proteolysis by elastase treat-
ment [12]. This segment probably corresponds to an
exposed loop at the surface of the FGE structure and the
impacts of the deletion on the stability and activity of
the corresponding variant cannot easily be predicted. In
Sabourdy et al. Orphanet Journal of Rare Diseases  (2015) 10:31 Page 12 of 14addition, the contribution of this mutant to the pheno-
type of Patient 5 is difficult to assess because it is pro-
duced from a transcript that is likely to be quantitatively
minor.
Two cases of p.G263V homozygosity, associated with
late infantile mild phenotypes, were recently reported
[27]. Structural and molecular analyses revealed that
p.G263V has a greater impact on the FGE protein
stability (confirmed by our expression analysis, Figure 1)
than on its catalytic activity, which averaged 15% of the wt
control [27]. These observations lead to the conclusion
that the p.G263V mutation induces a relatively attenuated
form of the disease. We report here a novel patient
homozygous for the p.G263V mutation (Patient 6).
His presentation, which was mainly neurological, was
also reminiscent of the late infantile mild subtype.
However, the patient’s condition worsened relatively
quickly. Thus, homozygosity for the p.G263V mutation
does not preclude a severe prognosis.
Patient 7 was homozygous for a mutation leading to a
large duplication encompassing exons 4 to 7, without
inducing a frameshift. Such a large duplication in the
SUMF1 gene has not previously been described. Surpris-
ingly, while this duplication mutant could be transiently
expressed in HEK293T cells, several attempts to obtain
stable transfectants in fibroblasts were unsuccessful. The
issue of whether the potential toxicity of this mutant
could account for the severe phenotype of this patient
remains to be investigated.
Patient 8 carried a nonsense mutation on one allele,
together with the well-characterised p.R349W substitu-
tion on the other allele. The p.R349W mutation has
already been reported in the Turkish population [17]. It
was shown to dramatically affect both the FGE stability
and catalytic activity, and was always associated, in an
homozygous context, with severe phenotypes [6,7,16,17].
The p.R236X mutation found in the other allele has not
previously been described. It induces the loss of 139
amino acids, including critical residues for the protein
stability and enzyme activity. Such a large modification
may prevent the protein from passing the endoplasmic
reticulum quality control system. In addition, the possi-
bility that the mRNA carrying a premature termination
codon is recognised and processed by mRNA decay
cannot be ruled out. As expected, the association of the
p.R349W and p.R236X mutations led to a severe pheno-
type that we qualified as an infantile severe form. Of
note, the sulfatase activities measured in the patient’s
leukocytes were very low.
A comparable genotype was found in Patient 9.
The p.R349W mutation was associated with a novel
nonsense mutation, p.V45fsX75. The same conclusions as
those drawn for Patient 8 regarding genotype–phenotype
correlations could be expected. Indeed, as shown in Table 1,the phenotypes of Patients 8 and 9 were strikingly similar,
including intrauterine manifestations, early presentation of
non-neurological symptoms, and rapid neurologic regres-
sion. In addition, these two patients shared the same non-
neurological symptoms. Finally, both patients died at an
early age.
Patient 10 proved to have a complex genotype. In
addition to several polymorphisms (data not shown), she
carried two missense mutations on one allele (paternally
inherited) and a splice site mutation on the other allele,
leading to exon 5 skipping. Skipping of exon 5 (albeit
through another genomic mutation) has already been
reported once in heterozygosity with the p.A279V muta-
tion, leading to a “moderate” phenotype [6]. Exon 5 skip-
ping induces the loss of two disulphide bonds that
appear to be essential for protein folding, and is there-
fore likely to have a profound impact on the enzyme
function. The other allele carried two missense muta-
tions, p.Y340H and p.N259S, which have not previously
been reported. Overexpression of each mutant indi-
vidually was of great interest in that case, because it
allowed us to identify the disease-causing mutation.
The p.Y340H mutation had little impact on the protein
stability, a finding in agreement with our structural ana-
lysis, which did not reveal any major modifications. Be-
sides, a p.Y340F mutant was previously reported to
conserve 74% of the wt enzyme activity [12]. Taken to-
gether, these data suggest that the Y340 substitution had
little impact on FGE. However, the p.N259S mutation ap-
peared to have much more severe consequences for the
FGE protein. We demonstrated that this mutation im-
paired FGE expression (Figure 1). The Asn259 residue is
thought to play a critical role in FGE stability, by partici-
pating in the coordination of one of the two structurally
important calcium ions [12] (see also Figure 3C, right). In
addition, a p.N259I mutant was previously shown to be
totally unable to activate arylsulfatases A, C, and E [16].
Finally, the p.N259S mutation appeared to largely con-
tribute, in association with exon 5 skipping, to the severe
phenotype of Patient 10.
Conclusions
This study provides new insights into MSD, a disorder
that remains poorly known. Special attention was paid
to highlighting signs and factors that could serve as
prognostic indicators. Based on clinical observations, the
presence of non-neurological symptoms before the age
of 2 years and the occurrence of psychomotor regression
around the same age appear to be associated with rapid
progression of the disease. Meanwhile, a correlation be-
tween the mean residual leukocyte sulfatase activities
and the clinical severity was observed, although the ac-
tivities of individual sulfatases were not reliable prognos-
tic markers. These findings are in line with previously
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correlations. The present findings confirm the involve-
ment of null mutations (e.g., p.R236X and p.V45fs75X)
or mutations that deeply modify the FGE sequence (exon
duplication or skipping) in severe phenotypes. Our re-
sults also demonstrate the severe impact of the p.R349W
mutation. Missense mutations that affect the protein ex-
pression (i.e., p.N259S and p.G263V) appear to be clearly
deleterious. However, missense mutations that moder-
ately affect the FGE stability and are not thought to dir-
ectly target the catalytic site (i.e., p.A279V and p.A298E)
seem to be associated with relatively milder phenotypes
and slower disease progression. Nevertheless, discrepan-
cies were noted for the p.R343S mutant, which was pre-
dicted by molecular analysis to be deeply damaging for
the FGE activity but was associated with the mildest
phenotype in this study. Full descriptions of additional
MSD patients should help to clarify the pathogenicity of
this and other mutants.
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